How does West Pharmaceutical Services (WST) make money?

West Pharmaceutical Services (WST) generates revenue primarily from Proprietary Products, which accounted for 85.4% of total revenue in TTM through Q1 2026. The company reported $3.22B in revenue and converted 16.9% of it into net profit, equivalent to roughly $542.70M in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of West Pharmaceutical Services (WST)?

West Pharmaceutical Services (WST) reported a gross profit margin of 36.2% in TTM through Q1 2026, equivalent to $1.17B in gross profit on $3.22B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of West Pharmaceutical Services (WST)?

West Pharmaceutical Services (WST) reported an operating profit margin of 20.7% in TTM through Q1 2026, equivalent to $665.60M in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of West Pharmaceutical Services (WST)?

West Pharmaceutical Services (WST) reported a net profit margin of 16.9% in TTM through Q1 2026, equivalent to $542.70M in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is West Pharmaceutical Services (WST) profitable?

Yes. West Pharmaceutical Services (WST) reported $542.70M in net income for TTM through Q1 2026, with a net profit margin of 16.9%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does West Pharmaceutical Services (WST) invest in research and development?

West Pharmaceutical Services (WST) invested $73.80M in research and development during TTM through Q1 2026, roughly 2.3% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does West Pharmaceutical Services (WST) spend on capital expenditures?

West Pharmaceutical Services (WST) spent $257.30M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 8.0% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does West Pharmaceutical Services (WST) generate?

West Pharmaceutical Services (WST) generated $458.00M in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 14.2%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of West Pharmaceutical Services (WST)?

West Pharmaceutical Services (WST) had an effective tax rate of 20.9% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of West Pharmaceutical Services (WST)?

West Pharmaceutical Services (WST) reports revenue across 2 reportable product segments, led by Proprietary Products at 85.4% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

How West Pharmaceutical Services Makes Money: 2026 Visual Revenue Map

West Pharmaceutical Services (WST) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 23, 2026).

West Pharmaceutical Services discloses geographic revenue only in annual filings. to view the full breakdown.

West Pharmaceutical Services (WST) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for West Pharmaceutical Services (WST) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Proprietary Products	$2.75B	85.4%
Contract Manufactured Products	$468.84M	14.6%
Total	$3.22B	100%

Proprietary Products$2.75B
Contract Manufactured Products$468.84M
Total$3.22B

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, West Pharmaceutical Services (WST) reports revenue across 2 operating segments; the largest segment was Proprietary Products at 85.4%, followed by Contract Manufactured Products (14.6%).

Frequently asked questions

Data & methodology

West Pharmaceutical Services (WST) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation